"The
Report Asthma Therapeutics Market to 2019 - Breakthrough Biologics to
Enhance Treatment of Severe Asthma and Drive Market Growth provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
GBI
Research, a leading business intelligence provider, has released its
latest research report “Asthma Market to 2019”. The asthma market
is forecast to grow marginally over the forecast period across the
leading eight developed nations, from $16.6 billion in 2012 to a
projected value of $21.6 billion in 2019. This growth is expected
despite the generic erosion facing the leading brands, and is a
consequence of new market entrants and a disease prevalence that
continues to rise, albeit not at rates as high as have been seen in
the past. Some new, costly asthma therapies could be set to enter the
asthma market, including GlaxoSmithKline’s (GSK’s) recently
approved Relvar (fluticasone/vilanterol), and multiple monoclonal
antibodies (mAbs).
These
include reslizumab, mepolizumab and lebrikizumab, which are being
developed by Teva, GSK and Roche respectively. The mAbs, in
particular, have the potential to change the asthma treatment
landscape, most notably with regards to severe forms of the disease.
Although such therapy may only play the role of an alternative
treatment in the asthma treatment algorithm, their ability to reduce
exacerbation rates has strong clinical and commercial value.
View Report At
:http://www.marketresearchreports.biz/analysis/176106
Scope
The report assesses the current
asthma market, and forecasts market trends to 2019, analyzing key
drivers and barriers. The areas covered include the following:
- A disease introduction, which defines the disease, including symptoms, diagnosis and treatment
- Analysis of the landscape of the asthma market, including a comparison of the efficacy and safety of the most prominent brands
- Detailed analysis of the asthma pipeline, including, among other parameters, details of drug distribution by phase, molecule type and mechanism of action. The asthma clinical trial landscape is then analyzed, with a particular emphasis on failure rates across phases as well as trends in clinical trial size and duration, and by mechanism of action. This section also includes single-product forecasts for the most promising pipeline drugs.
- An in-depth forecasting model for the asthma market, which considers the current marketed therapies, in addition to the potential market entry of new products. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies.
- Analysis of strategic consolidations within the asthma indication, including co-development and licensing agreements
- An overview of the drivers and barriers for the asthma market
Download
Sample copy of this Report at :
Reasons to Buy
Primarily, the report will enable
clients to establish a strong understanding of the asthma indication,
helping to identify and understand market opportunities and the
emerging competitive environment. It will also enable you to:
- Understand the asthma pipeline and the factors that indicate that it is becoming more innovative. This is highlighted by the presence of numerous biologics in the pipeline, which look set to have a major impact upon the asthma market.
- Observe detailed profiles for promising pipeline products, including revenue forecasts, and gain insights into how they are likely to compete in the market and who their main competitors will be.
- Follow the trends in asthma clinical trial size and duration in relation to industry averages. In addition, the report will enable you to assess the potential risk of future developmental programs for asthma therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates.
- Observe the potential growth patterns expected for the asthma market over the forecast period, and identify which countries are expected to contribute the most to this growth.
Table
of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Assessment of Disease Severity
2.7 Treatment
2.8 Treatment Algorithm
3 Marketed Products
3.1 Product Profiles
3.1.1 Advair Diskus (fluticasone
and salmeterol) – GlaxoSmithKline
3.1.2 Symbicort
(budesonide/formoterol) – AstraZeneca, Co-promotion with Astellas
Pharma Inc
3.1.3 Singulair (montelukast) –
Merck & Co
3.1.4 Xolair (omalizumab) –
Novartis and Genentech
3.1.5 Foradil (formoterol) –
Novartis (Co-marketed by Novartis and Schering Corporation)
3.1.6 Dulera/Zenhale
(mometasone/formoterol) – Merck & Co
3.1.7 Relvar/Breo –
GlaxoSmithKline/Theravance
4 Asthma Pipeline
4.1 Overview
4.2 Mechanisms of Action in the
Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.3.4 Comparative Clinical Trial
Metrics Analysis
4.4 Promising Pipeline Molecules
4.4.1 Reslizumab – Teva
Pharmaceutical ltd
4.4.2 Mepolizumab -
GlaxoSmithKline
4.4.3 Lebrikizumab –
Roche/Genentech
4.4.4 Veramyst - GlaxoSmithKline
4.4.5 Andolast – Rottapharm
Madaus
4.4.6 Spiriva (Tiotropium Bromide)
– Boehringer Ingelheim
4.5 Heat Map of Safety and
Efficacy for Pipeline and Marketed Products
5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Market
5.1.2 North America
5.1.3 Top Five Countries of Europe
5.1.4 Japan
5.2 Drivers and Barriers for the
Asthma Therapeutics Market
5.2.1 Drivers
5.2.2 Barriers
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment